Your browser doesn't support javascript.
loading
Treatment Patterns and Outcomes Among Elderly Glioblastoma Patients in Riyadh, Saudi Arabia.
Marie, Amal; Maklad, Ahmed; AlTwairgi, Abdullah; Aly, Moemen; Elyamany, Ashraf; AlShaqweer, Wafaa; Senosy, Mohamed; Balbaid, Ali.
Afiliação
  • Marie A; Department of Radiation Oncology, Comprehensive Cancer Centre, King Fahad Medical City, Riyadh, Saudi Arabia.
  • Maklad A; Clinical Oncology Department, Ain Shams University, Cairo, Egypt.
  • AlTwairgi A; Department of Radiation Oncology, Comprehensive Cancer Centre, King Fahad Medical City, Riyadh, Saudi Arabia.
  • Aly M; Clinical Oncology Department, Sohag University, Sohag, Egypt.
  • Elyamany A; Department of Medical Oncology, King Fahad Medical City, Riyadh, Saudi Arabia.
  • AlShaqweer W; Department of Radiation Oncology, Comprehensive Cancer Centre, King Fahad Medical City, Riyadh, Saudi Arabia.
  • Senosy M; Department of Radiotherapy and Nuclear Medicine, South Egypt Cancer Institute, Assiut University, Assiut, Egypt.
  • Balbaid A; Medical Oncology Department, SECI, Assiut University, Egypt/KSMC, Riyadh, Saudi Arabia.
Onco Targets Ther ; 15: 135-144, 2022.
Article em En | MEDLINE | ID: mdl-35140474
ABSTRACT

BACKGROUND:

Management of elderly patients with glioblastoma (GBM) is a controversial scenario and needs careful assessment and selection for aggressive radical treatment and chemotherapy protocols vs short-course radiotherapy without chemotherapy.

METHODS:

We evaluated treatment patterns and outcome among elderly GBM patients treated in KFMC, Riyadh. The primary endpoint is overall survival (OS) and the secondary endpoint is progression-free survival (PFS); patients were reviewed regarding radiotherapy (Rth) fractionation modalities, surgery, and chemotherapy (CTR) given in correlation to PFS, OS.

RESULTS:

Fifty-nine patients were recruited in our study with median age 66 (range 60-81) years, and 47 (80%) were males. Thirty-seven patients (62.7%) had ECOG performance status (PS) ≥2, and 22 patients (37.3%) had PS <2. Gross total resection (GTR) and subtotal resection (STR) were done in 49 (82.9%) patients, and the median follow-up was 12 months. Thirty-eight (64%) patients received conventional Rth 60 Gray (Gy)/30 fractions or equal doses and 21 (36%) patients received hypofractionation Rth (40 Gy/15, 25 Gy/5 or 30 Gy/10 fractions). The median OS was 12 months (95%CI 9.52-14.48). Receiving conventional Rth and completion of six months adjuvant CTR were significant factors for O.S (P=0.043 and 0.026), respectively. The median PFS was nine months (95%CI 6.13-11.87). For univariate analysis, PS, time to start adjuvant treatment, and completion of six months CTR were significant factors for PFS.

CONCLUSION:

Conventional Rth and completion of adjuvant CTR lead to better OS, while earlier start of adjuvant treatment and the completion of adjuvant CTR were associated with a better PFS.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Guideline Idioma: En Revista: Onco Targets Ther Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Guideline Idioma: En Revista: Onco Targets Ther Ano de publicação: 2022 Tipo de documento: Article